Search

everythinglearnresearchcommunity

for

Search:↓

5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.

Chemotherapy in the first trimester of pregnancy is risky, but in the second and third trimesters, it's generally safe with careful drug selection and timing.

Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Trastuzumab may cause tufted hair folliculitis as a side effect.

Orlistat might block the body's ability to absorb thyroid medication.

Hippocampus sparing whole brain radiation therapy prevents hair loss and preserves cognitive function.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Finasteride does not prevent bladder cancer.

Early detection and complete surgical removal are crucial for better outcomes in treating pilomatrix carcinoma.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Scalp hypothermia can prevent chemotherapy-induced hair loss but is not suitable for all patients, and more research is needed to improve prevention methods.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

Low-dose radiation therapy may improve brain function in some Alzheimer's patients and is generally well-tolerated.

Living with metastatic pancreatic cancer involves symptoms like fatigue and nausea, and impacts like anxiety and reduced physical function.

LncRNAs may help improve brain cancer treatment and diagnosis.

Blocking both P-cadherin and c-Met can effectively stop head and neck cancer growth.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.

The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.

Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Higher doses of cranial irradiation are linked to permanent hair loss.